达西高血糖素——一种用于快速有效治疗严重低血糖的下一代高血糖素类似物:3期随机双盲临床试验结果
这项随机双盲3期试验纳入170例1型糖尿病成人,在控制性胰岛素诱导低血糖期间随机接受单次皮下0.6 mg达西高血糖素、安慰剂或1 mg重组高血糖素(2:1:1)。达西高血糖素恢复血糖中位时间10分钟,优于安慰剂40分钟(P<0.001),与重组高血糖素12分钟相似;最常见不良反应为恶心和呕吐。
要点
- 达西高血糖素组血糖恢复中位时间10分钟,安慰剂组40分钟(P<0.001)。
- 达西高血糖素组99%受试者15分钟内血糖恢复,安慰剂组2%(P<0.001)。
- 达西高血糖素安全性和耐受性与重组高血糖素注射相似。
核心结论
- 达西高血糖素可快速有效逆转1型糖尿病成人的低血糖,安全性和耐受性与重组高血糖素注射相似。
- 达西高血糖素的即用型水剂配方有潜力为严重低血糖提供快速可靠的治疗。
研究设计与样本
- 随机、双盲3期试验纳入170例1型糖尿病成人参与者,在控制性胰岛素诱导低血糖期间随机接受单次皮下0.6 mg达西高血糖素、安慰剂或1 mg重组高血糖素(2:1:1随机化)。
- 主要终点为血糖恢复时间,定义为从基线增加≥20 mg/dL且未使用静脉抢救葡萄糖;主要比较为达西高血糖素 versus 安慰剂,重组冻干高血糖素作为参考。
主要发现
- 血糖恢复中位时间(95%CI)达西高血糖素组为10(10,10)分钟,安慰剂组为40(30,40)分钟(P<0.001);重组高血糖素组相应结果为12(10,12)分钟。
- 达西高血糖素组除一名参与者外全部在15分钟内实现血糖恢复(99%),优于安慰剂组(2%;P<0.001),与高血糖素组(95%)相似。
- 给药后10、20和30分钟的其他考察时间点观察到相似结果。
- 最常见的不良反应为恶心和呕吐,与高血糖素治疗的预期一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of dasiglucagon, a ready-to-use, next-generation glucagon analog in aqueous formulation for subcutaneous dosing, for treatment of severe hypoglycemia in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: This randomized, double-blind trial included 170 adult participants with type 1 diabetes, each randomly assigned to receive a single subcutaneous dose of 0.6 mg dasiglucagon, placebo, or 1 mg reconstituted glucagon (2:1:1 randomization) during controlled insulin-induced hypoglycemia. The primary end point was time to plasma glucose recovery, defined as an increase of ≥20 mg/dL from baseline without rescue intravenous glucose. The primary comparison was dasiglucagon versus placebo; reconstituted lyophilized glucagon was included as reference. RESULTS: Median (95% CI) time to recovery was 10 (10, 10) minutes for dasiglucagon compared with 40 (30, 40) minutes for placebo (P < 0.001); the corresponding result for reconstituted glucagon was 12 (10, 12) minutes. In the dasiglucagon group, plasma glucose recovery was achieved within 15 min in all but one participant (99%), superior to placebo (2%; P < 0.001) and similar to glucagon (95%). Similar outcomes were observed for the other investigated time points at 10, 20, and 30 min after dosing. The most frequent adverse effects were nausea and vomiting, as expected with glucagon treatment. CONCLUSIONS: Dasiglucagon provided rapid and effective reversal of hypoglycemia in adults with type 1 diabetes, with safety and tolerability similar to those reported for reconstituted glucagon injection. The ready-to-use, aqueous formulation of dasiglucagon offers the potential to provide rapid and reliable treatment of severe hypoglycemia.
引用
- Pieber TR, Aronson R, Hövelmann U, et al. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care. 2021. PMID: 35239971. doi:10.2337/dc20-2995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。